In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
New investor Bay City Capital led a $32mm Series B round for cancer therapeutics developer Epizyme. Also participating were additional new buyers Amgen Ventures and Astellas Venture Management, as well as returning backers Kleiner Perkins Caufield & Byers and MPM Capital. Bay City's managing director will take a seat on Epizyme's board.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?